Stimulation of epithelial repair is a likely mechanism for the action of mifepristone in reducing duration of bleeding in users of progestogen-only contraceptives.
Many women using progestogen (P)-only contraceptives experience uterine bleeding problems. In clinical trials, a single low dose of mifepristone, given to Implanon users at the beginning of a bleeding episode reduced the number of bleeding days by approximately 50% compared with controls. In this study, a single dose of mifepristone was administered to etonogestrel (ENG)-exposed pseudo-pregnant mice, 5 days after artificial decidualization was induced when the endometrium showed signs of bleeding. Control mice received vehicle alone. Mice were culled 12-, 18-, 24- and 48-h post-treatment. In the continued presence of ENG, a single dose of mifepristone stimulated tissue breakdown followed by very rapid repair: most treated tissues were fully restored to the pre-decidualized state by 48 h post-treatment. During repair, proliferating cells (Ki67 immunostained) were localized to a band of cells around the basal area in breaking down tissues and to the repairing luminal epithelium and glands. Progesterone receptor-positive cells were largely localized to the basal area of the breaking down tissue in treated mice compared with decidual cells in controls. Oestrogen receptor-positive cells were observed in the repairing luminal epithelium and glands compared with the decidua and the basal region in control tissues. It is concluded that mifepristone treatment stimulates rapid restoration of luminal epithelial integrity: such action may be a key event in reducing the number of bleeding days observed in women using Implanon who were treated with a single dose of mifepristone.
Morison
Naomi B
NB
Prince Henry's Institute, Level 4 Block E, Monash Medical Centre, 246 Clayton Rd, Clayton, Victoria 3168, Australia.
Kaitu'u-Lino
Tu'uhevaha J
TJ
Fraser
Ian S
IS
Salamonsen
Lois A
LA
D000818:Animals; D003280:Contraceptives, Oral, Synthetic / Q000494:pharmacology*; D004717:Endometrium / Q000187:drug effects; D047628:Estrogen Receptor alpha / Q000032:analysis; D005260:Female; D006470:Hemorrhage / Q000188:drug therapy*; D006801:Humans; D007150:Immunohistochemistry; D007279:Injections, Subcutaneous; D007633:Keratins / Q000032:analysis; D051379:Mice; D008810:Mice, Inbred C57BL; D015735:Mifepristone / Q000494:pharmacology*; D023421:Models, Animal; D011372:Progestins / Q000378:metabolism*; D011555:Pseudopregnancy; D011980:Receptors, Progesterone / Q000032:analysis; D013268:Stimulation, Chemical; D014945:Wound Healing
D003280:Contraceptives, Oral, Synthetic; D047628:Estrogen Receptor alpha; D011372:Progestins; D011980:Receptors, Progesterone; D015735:Mifepristone; D007633:Keratins